Description
Product Classification: Research-Use-Only (RUO)
Total Content: 10 mg lyophilized powder per vial
Compound: Tirzepatide research analog
Form: Sterile lyophilized peptide compound
Purity: ≥99%
Storage: Store at −20 °C, protected from light
Packaging: Glass vial in protective sleeve
Description
Tirzepatide 10 mg is a tirzepatide research analog designed for laboratory investigation of dual incretin receptor signaling. Tirzepatide is studied as a dual receptor agonist model involving GLP-1 and GIP receptor pathways. This dual-pathway profile makes it useful for preclinical research into metabolic regulation, glucose signaling, energy balance, receptor cross-talk, and metabolic pathway modeling.
This compound is intended strictly for in vitro and preclinical laboratory research.
Applications
Intended for preclinical laboratory research only, including:
- GLP-1 receptor signaling studies
- GIP receptor pathway research
- Dual incretin pathway analysis
- Metabolic regulation investigations
- Energy-balance pathway studies
- Glucose signaling experiments
- Comparative incretin analog research
WARNING: Not for human or animal use. For research purposes only.
SCIENTIFIC REPORT
Abstract
Tirzepatide is a synthetic dual receptor agonist investigated for activity at GLP-1 and GIP receptors. This dual-pathway profile allows researchers to model complementary incretin signaling systems in controlled experimental environments. Tirzepatide 10 mg is designed for laboratory use in studies examining metabolic signaling, receptor selectivity, energy regulation, glucose pathway activity, and downstream cellular responses associated with incretin receptor activation.
Mechanistic Pathway
Tirzepatide is designed around dual incretin receptor pathway modeling.
- GLP-1 Receptor Pathway
- Supports research into incretin signaling
- Used in glucose-regulatory pathway models
- Studied for effects on downstream metabolic signaling
Effect: Models GLP-1 receptor activity in controlled research systems.
GIP Receptor Pathway
- Supports investigation of GIP-associated signaling
- Used in models of metabolic pathway interaction
- Helps study receptor cross-talk in incretin systems
Effect: Enables research into GIP pathway contribution to dual-receptor metabolic signaling.
Dual Incretin Signaling Pathway
- Supports research into combined incretin receptor activity
- Used in metabolic regulation and glucose signaling models
- Helps evaluate interaction between complementary incretin pathways
Effect: Provides a model for dual incretin pathway regulation research.
Pharmacokinetics / Research Profile
- Compound
- Pathway
- Research Notes
- Tirzepatide analog
- GLP-1R / GIPR
- Dual receptor agonist model for metabolic pathway research
Dosing Models in Research
Used only in controlled in vitro and preclinical research models to study receptor signaling and metabolic pathway response. No human or animal-use instructions are provided.
Preclinical Research Highlights
- Studied as a dual agonist model involving GLP-1 and GIP receptors
- Used in metabolic regulation and energy-balance pathway research
- Supports comparative studies with single and multi-receptor incretin models
- Relevant to glucose signaling, receptor interaction, and pathway cross-talk studies
- Useful for evaluating downstream effects of dual-receptor peptide signaling
Conclusion
Tirzepatide 10 mg offers a research-use-only model for studying dual incretin receptor pathway activation. By engaging GLP-1 and GIP receptor signaling models, it supports advanced preclinical investigation into metabolic regulation, receptor cross-talk, glucose pathway signaling, energy balance, and incretin pathway interactions.
